Literature DB >> 2557217

Plasma beta-endorphin, ACTH and cortisol secretion in man after nasal spray administration of calcitonin.

R Franceschini1, A Cataldi, T Barreca, M Salvemini, E Rolandi.   

Abstract

Beta-endorphin, ACTH and cortisol secretion were measured in twelve healthy adult males after nasal spray administration 200 IU salmon calcitonin. A significant increase in plasma beta-endorphin, from 19.2 ng/l under basal conditions to a peak of 27.1 ng/l at 30 min was recorded. Plasma ACTH and cortisol were not affected. In individual subjects the beta-endorphin level was increased in eight of the twelve, ACTH rose in three and cortisol did not change in any of them. The data indicate that calcitonin induced a beta-endorphin increase independent of enhanced corticotrophin-cortisol release.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2557217     DOI: 10.1007/BF00558497

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Lack of opiate receptor involvement in centrally induced calcitonin analgesia.

Authors:  P Braga; S Ferri; A Santagostino; V R Olgiati; A Pecile
Journal:  Life Sci       Date:  1978-03       Impact factor: 5.037

2.  Effectiveness of salmon calcitonin nasal spray preparation in migraine treatment.

Authors:  G Micieli; A Cavallini; E Martignoni; V Covelli; F Facchinetti; G Nappi
Journal:  Headache       Date:  1988-04       Impact factor: 5.887

3.  Radioimmunoassay of ACTH in plasma.

Authors:  S A Berson; R S Yalow
Journal:  J Clin Invest       Date:  1968-12       Impact factor: 14.808

4.  Effect of calcitonin on prolactin release in rats.

Authors:  Y Iwasaki; K Chihara; J Iwasaki; H Abe; T Fujita
Journal:  Life Sci       Date:  1979-10-01       Impact factor: 5.037

5.  Calcitonin and prostaglandin system.

Authors:  R Ceserani; M Colombo; V R Olgiati; A Pecile
Journal:  Life Sci       Date:  1979-11-19       Impact factor: 5.037

6.  Intranasal absorption of salmon calcitonin.

Authors:  H Kurose; Y Seino; M Shima; H Tanaka; M Ishida; K Yamaoka; H Yabuuchi
Journal:  Calcif Tissue Int       Date:  1987-11       Impact factor: 4.333

7.  Pharmacokinetic study with synthetic salmon calcitonin (Sandoz).

Authors:  T Beveridge; W Niederer; E Nüesch; A Petrin
Journal:  Z Gastroenterol Verh       Date:  1976

8.  Calcitonin induced increase in ACTH, beta-endorphin and cortisol secretion.

Authors:  L Laurian; Z Oberman; E Graf; S Gilad; E Hoerer; R Simantov
Journal:  Horm Metab Res       Date:  1986-04       Impact factor: 2.936

9.  The analgesic effect of calcitonin in humans: studies on the role of opioid peptides.

Authors:  A Fabbri; C Santoro; C Moretti; M Cappa; F Fraioli; G P Di Julio; T Galluzzi; V La Manna
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1981-11

10.  Human plasma beta-endorphin-like peptides: a rapid, high recovery extraction technique and validation of radioimmunoassay.

Authors:  C A Cahill; J D Matthews; H Akil
Journal:  J Clin Endocrinol Metab       Date:  1983-05       Impact factor: 5.958

View more
  9 in total

Review 1.  Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.

Authors:  G L Plosker; D McTavish
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

2.  Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial.

Authors:  Michio Hongo; Naohisa Miyakoshi; Yuji Kasukawa; Yoshinori Ishikawa; Yoichi Shimada
Journal:  J Bone Miner Metab       Date:  2014-08-15       Impact factor: 2.626

3.  The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain.

Authors:  D Ofluoglu; G Akyuz; O Unay; O Kayhan
Journal:  Clin Rheumatol       Date:  2006-03-31       Impact factor: 2.980

Review 4.  Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging.

Authors:  S P Clissold; A Fitton; P Chrisp
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

Review 5.  Understanding osteoporotic pain and its pharmacological treatment.

Authors:  R Vellucci; R Terenzi; J A Kanis; H G Kress; R D Mediati; J-Y Reginster; R Rizzoli; M L Brandi
Journal:  Osteoporos Int       Date:  2018-04-04       Impact factor: 4.507

6.  Inhibitory effects of salmon calcitonin on the tail-biting and scratching behavior induced by substance P and three excitatory amino acids.

Authors:  Y Maeda; K Yamada; T Hasegawa; M Iyo; S Fukui; T Nabeshima
Journal:  J Neural Transm Gen Sect       Date:  1994

7.  Lack of stimulatory effect of 1,25(OH)2 vitamin D3 on beta-endorphin and cortisol secretion.

Authors:  I Zofková; R L Kancheva
Journal:  J Endocrinol Invest       Date:  1994-10       Impact factor: 4.256

Review 8.  The effects of beta-endorphin: state change modification.

Authors:  Jan G Veening; Henk P Barendregt
Journal:  Fluids Barriers CNS       Date:  2015-01-29

9.  Clinical efficacy of calcitonin compared to diclofenac sodium in chronic nonspecific low back pain with type I Modic changes: a retrospective study.

Authors:  Jiaming Zhou; Tengshuai Li; Liandong Li; Yuan Xue
Journal:  J Pain Res       Date:  2018-07-17       Impact factor: 3.133

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.